Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis

被引：11

作者：

Hu, Fei ^{[1
]}

Chen, Li ^{[1
]}

Bi, Ming-Yu ^{[1
]}

Zheng, Ling ^{[1
]}

He, Ji-Xiang ^{[1
]}

Huang, Ying-Ze ^{[1
]}

Zhang, Yu ^{[2
]}

Zhang, Xue-Lian ^{[2
]}

Guo, Qiang ^{[2
]}

Luo, Ying ^{[1
,2
]}

Tang, Wen-Ru ^{[1
]}

Sheng, Miao-Miao ^{[1
,2
]}

机构：

[1] Kunming Univ Sci & Technol, Med Sch, Lab Mol Genet Aging & Tumor, Chenggong Campus,727 South Jingming Rd, Kunming 650500, Yunnan, Peoples R China

[2] First Peoples Hosp Yunnan Prov, Yunnan Prov Inst Digest Med, 157 Jinbi Rd, Kunming 650500, Yunnan, Peoples R China

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2020年 / 216卷 / 08期

基金：

中国国家自然科学基金;

关键词：

RASSF1A; Methylation; Colorectal cancer; Meta-analysis; TCGA analysis; CPG ISLAND HYPERMETHYLATION; DNA METHYLATION; GENES; TUMOR;

D O I：

10.1016/j.prp.2020.153009

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The RAS association domain family protein 1A (RASSF1A) is a tumor suppressor in colorectal cancer (CRC), and is often inactived by hypermethylation. Therefore, we evaluated the association between RASSF1A hypermethylation and the risk and prognosis in CRC. We identified literature through searching PubMed and China National Knowledge Infrastructure databases, and then validated and supplemented the meta-analysis with TCGA analysis. Twenty-three studies involving 2886 subjects of CRC were examined. The meta-analysis showed that RASSF1A promoter methylation inferred high CRC risk (odds ratio, 6.53, 95% confidence interval 3.88-11.01, P < .001) and poor overall survival (hazard ratio 2.85, 95% CI 1.88-4.31, P < .001). The TCGA analysis suggested that effect of RASSF1A promotor methylation was affected by tumor localization (colon vs. rectum). RASSFIA promoter methylation was a predictor of high risk (OR 2.38, 95%CI 1.02-5.6, P = .046) and poor disease free survival(HR 2.25, 95%CI 1.27-3.99, P = .006)in colon adenocarcinoma, but the association was statistically insignificant in rectum adenocarcinoma(HR 1.58, 95% CI 0.69-3.59, P = .28). These results suggested RASSF1A hypermethylation is a risk and a potential prognostic biomarker in CRC.

引用

页数：7